Biogen Inc
BIIB118.840USD
-0.670-0.56%
收盤 04/25, 16:00（美東）報價延遲15分鐘
17.31B總市值
10.61本益比TTM
關於 Biogen Inc 公司
Biogen Inc. 是一家全球性生物製藥公司。該公司致力於爲全球患有嚴重和複雜疾病的人們發現、開發和提供先進的治療方法。該公司經營一系列藥物，用於治療多發性硬化症 (MS)、脊髓性肌萎縮症 (SMA)、阿爾茨海默病和肌萎縮側索硬化症 (ALS)。該公司專注於推進其在神經病學、專業免疫學和罕見疾病領域的產品線。其上市產品包括用於治療 MS 的 TECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI 和 FAMPYRA；用於治療 SMA 的 SPINRAZA；用於治療弗裏德賴希共濟失調的 SKYCLARYS；用於治療 ALS 的 QALSODY 和用於治療嚴重斑塊狀銀屑病的 FUMADERM。它還與 Eisai 合作，將 LEQEMBI 商業化，用於治療阿爾茨海默病，並與 Sage 合作，將 ZURZUVAE 商業化，用於治療產後抑鬱症 (PPD)。
公司簡介
公司代碼BIIB
公司名稱Biogen Inc
上市日期Sep 17, 1991
成立日期1997
CEOMr. Christopher A. (Chris) Viehbacher
員工數量7605
證券類型Ordinary Share
年結日Sep 17
公司地址225 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話17814642000
網址https://www.biogen.com/
公司代碼BIIB
上市日期Sep 17, 1991
成立日期1997
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
36.27K
+14.76%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
25.03K
+7.68%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.06K
+45.88%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
13.45K
+38.65%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
10.36K
-45.82%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.88K
+36.82%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
6.43K
+26.34%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
3.48K
+62.47%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
1.90K
+187.01%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
36.27K
+14.76%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
25.03K
+7.68%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.06K
+45.88%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
13.45K
+38.65%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
10.36K
-45.82%
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Spinal Muscular Atrophy-SPINRAZA
1.99B
20.55%
MS product revenues-TYSABRI
1.72B
17.72%
MS product revenues-Fumarate
1.60B
16.49%
MS product revenues-Interferon
968.00M
10.00%
Biosimilar product revenues-BENEPALI
479.10M
4.95%
Other
2.93B
30.29%
地區USD
名稱
營收
佔比
Rest of World
3.98B
41.09%
United States
3.30B
34.08%
United states-Revenues from anti-CD20 therapeutic
1.75B
18.09%
Rest of World-Other revenues
652.60M
6.74%
業務
地區
業務USD
名稱
營收
佔比
Spinal Muscular Atrophy-SPINRAZA
1.99B
20.55%
MS product revenues-TYSABRI
1.72B
17.72%
MS product revenues-Fumarate
1.60B
16.49%
MS product revenues-Interferon
968.00M
10.00%
Biosimilar product revenues-BENEPALI
479.10M
4.95%
Other
2.93B
30.29%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.39%
PRIMECAP Management Company
10.96%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
5.05%
Wellington Management Company, LLP
3.37%
Other
63.35%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
11.39%
PRIMECAP Management Company
10.96%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Global Advisors (US)
5.05%
Wellington Management Company, LLP
3.37%
Other
63.35%
股東類型
股東統計
佔比
Investment Advisor
43.69%
Investment Advisor/Hedge Fund
36.85%
Hedge Fund
5.46%
Research Firm
2.82%
Pension Fund
2.29%
Bank and Trust
1.74%
Sovereign Wealth Fund
1.67%
Private Equity
0.35%
Individual Investor
0.15%
Other
4.99%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
2074
138.81M
94.83%
-5.05M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
2023Q1
2280
132.71M
91.84%
-5.88M
2022Q4
2292
132.00M
91.64%
-4.78M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
16.68M
11.39%
+1.13K
+0.01%
Dec 31, 2024
PRIMECAP Management Company
16.05M
10.96%
-268.87K
-1.65%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.59M
5.87%
+23.69K
+0.28%
Dec 31, 2024
State Street Global Advisors (US)
7.40M
5.05%
+53.29K
+0.73%
Dec 31, 2024
Wellington Management Company, LLP
4.93M
3.37%
-200.47K
-3.91%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.70M
2.52%
+82.46K
+2.28%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
3.10M
2.12%
-1.16M
-27.17%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
3.01M
2.06%
+40.53K
+1.36%
Feb 28, 2025
Pacer Advisors, Inc.
2.67M
1.82%
+2.65M
+13.57K%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
2.33M
1.59%
+246.45K
+11.86%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Invesco Biotechnology & Genome ETF
4.41%
iShares Neuroscience and Healthcare ETF
3.82%
Global X US Cash Flow Kings 100 ETF
3.55%
VanEck Biotech ETF
3.23%
Tema Neuroscience and Mental Health ETF
3.15%
Alger Russell Innovation ETF
3.04%
First Trust NYSE Arca Biotechnology Index Fund
2.94%
First Trust NASDAQ Pharmaceuticals ETF
2.89%
Invesco Pharmaceuticals ETF
2.39%
SPDR S&P Biotech ETF
2.19%
查看更多
Invesco Biotechnology & Genome ETF
佔比4.41%
iShares Neuroscience and Healthcare ETF
佔比3.82%
Global X US Cash Flow Kings 100 ETF
佔比3.55%
VanEck Biotech ETF
佔比3.23%
Tema Neuroscience and Mental Health ETF
佔比3.15%
Alger Russell Innovation ETF
佔比3.04%
First Trust NYSE Arca Biotechnology Index Fund
佔比2.94%
First Trust NASDAQ Pharmaceuticals ETF
佔比2.89%
Invesco Pharmaceuticals ETF
佔比2.39%
SPDR S&P Biotech ETF
佔比2.19%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據